-
Je něco špatně v tomto záznamu ?
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group
Y. Herishanu, A. Shaulov, R. Fineman, S. Bašić-Kinda, A. Aviv, E. Wasik-Szczepanek, O. Jaksic, M. Zdrenghea, U. Greenbaum, I. Mandac, M. Simkovic, M. Morawska, O. Benjamini, M. Spacek, A. Nemets, O. Bairey, L. Trentin, R. Ruchlemer, L. Laurenti,...
Jazyk angličtina Země Spojené státy americké
Typ dokumentu klinické zkoušky, časopisecké články, multicentrická studie, pozorovací studie
Odkazy
PubMed
32096887
DOI
10.1002/ajh.25766
Knihovny.cz E-zdroje
- MeSH
- chlorambucil aplikace a dávkování škodlivé účinky MeSH
- chromozomální delece * MeSH
- chronická lymfatická leukemie * farmakoterapie genetika mortalita MeSH
- humanizované monoklonální protilátky aplikace a dávkování škodlivé účinky MeSH
- lidé MeSH
- lidské chromozomy, pár 17 genetika MeSH
- míra přežití MeSH
- nádorový supresorový protein p53 genetika MeSH
- přežití po terapii bez příznaků nemoci MeSH
- protokoly antitumorózní kombinované chemoterapie aplikace a dávkování škodlivé účinky MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- multicentrická studie MeSH
- pozorovací studie MeSH
In recent years, considerable progress has been made in frontline therapy for elderly/physically unfit patients with CLL. The combination of obinutuzumab and chlorambucil (O-Clb) has been shown to prolong progression free survival (PFS, median PFS-31.5 months) and overall survival (OS) compared to chlorambucil alone. More recently, obinutuzumab given in combination with either ibrutinib or venetoclax improved PFS but not OS when compared to O-Clb. In this retrospective multinational, multicenter co-operative study, we evaluated the efficacy and safety of frontline treatment with O ± Clb in unfit patients with CLL, in a "real-world" setting. Patients with documented del (17p13.1)/TP53 mutation were excluded. A total of 437 patients (median age, 75.9 years; median CIRS score, 8; median creatinine clearance, 61.1 mL/min) were included. The clinical overall response rate was 80.3% (clinical complete and partial responses in 38.7% and 41.6% of patients, respectively). Median observation time was 14.1 months and estimated median PFS was 27.6 months (95% CI, 24.2-31.0). In a multivariate analysis, high-risk disease [del (11q22.3) and/or IGHV-unmutated], lymph nodes of diameter > 5 cm, obinutuzumab monotherapy and reduced cumulative dose of obinutuzumab, were all independently associated with shorter PFS. The median OS has not yet been reached and estimated 2-year OS is 88%. In conclusion, in a "real-world" setting, frontline treatment with O-Clb achieves PFS comparable to that reported in clinical trials. Inferior outcomes were noted in patients with del (11q22.3) and/or unmutated IGHV and those treated with obinutuzumab-monotherapy. Thus, O-Clb can be still considered as legitimate frontline therapy for unfit CLL patients with low-risk disease.
Barzilai University Medical Center Ashkelon Israel
Ben Gurion University Soroka University Medical Center Beer Sheva Israel
Charles University and General Hospital Prague Prague Czech Republic
Clinical Hospital Merkur Zagreb Croatia
Coltea Clinical Hospital Bucharest Romania
Department Hematology Oncology Azienda Ospedaliera Pugliese Ciaccio Catanzaro Italy
Department of Hematology Rambam Health Care Campus Haifa Israel
Department of Hematology Shaare Zedek Medical Center Jerusalem Israel
Department of Hematology Tel Aviv Sourasky Medical Center Tel Aviv Israel
Department of Hematooncology and Bone Marrow Transplantation Medical University Lublin Poland
Department of Molecular Biotechnology and Health Sciences University of Torino Torino Italy
Division of Hematology Cantonal Hospital of Lucerne Lucerne Switzerland
Division of Hematology Jewish General Hospital Montreal Quebec Canada
Dubrava University Hospital Zagreb Croatia
Emergency University Clinical Hospital Bucharest Romania
Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome Italy
Galilee Medical Center Nahariya Israel
Hadassah Hebrew University Medical Center Jerusalem Israel
Hematology and Hemotherapy Hospital Universitario Ramón y Cajal Madrid Spain
Hematology Bnai Zion Medical Center Haifa Israel
Hematology Colentina Clinical Hospital Bucharest Romania
Hematology Section 1st Department Of Propaedeutic Internal Medicine Laikon Hospital Athens Greece
Hematology Unit and Biotechnology Research Unit A O of Cosenza Cosenza Italy
Hematology Unit University of Padua Padua Italy
Hospital 12 de Octubre Madrid Spain
Hospital Alvarez Buenos Aires Argentina
Hospital Costa del Sol Marbella Spain
Hospital del Mar Barcelona Spain
Hospital General Universitario Valencia Spain
IIS IP Hospital Universitario de La Princesa Madrid Spain
Institut Jules Bordet Brussels Belgium
Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca Romania
Maxima Medical Center Eindhoven Veldhoven Eindhoven Netherlands
Rabin Medical Center Beilinson Hospital
Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel
St John's Cancer Center Lublin Poland
University Hospital and Medical School Hradec Kralove Hradec Kralove Czech Republic
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20023005
- 003
- CZ-PrNML
- 005
- 20201214125112.0
- 007
- ta
- 008
- 201125s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/ajh.25766 $2 doi
- 035 __
- $a (PubMed)32096887
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Herishanu, Yair $u Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.
- 245 10
- $a Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group / $c Y. Herishanu, A. Shaulov, R. Fineman, S. Bašić-Kinda, A. Aviv, E. Wasik-Szczepanek, O. Jaksic, M. Zdrenghea, U. Greenbaum, I. Mandac, M. Simkovic, M. Morawska, O. Benjamini, M. Spacek, A. Nemets, O. Bairey, L. Trentin, R. Ruchlemer, L. Laurenti, O. Stanca Ciocan, M. Doubek, L. Shvidel, N. Dali, F. Mirás, A. De Meûter, M. Dimou, FR. Mauro, M. Coscia, H. Bumbea, R. Szász, T. Tadmor, O. Gutwein, M. Gentile, L. Scarfò, A. Tedeschi, P. Sportoletti, E. Gimeno Vázquez, J. Marquet, S. Assouline, M. Papaioannou, A. Braester, L. Levato, M. Gregor, GM. Rigolin, J. Loscertales, A. Medina Perez, MR. Nijziel, VM. Popov, R. Collado, I. Slavutsky, G. Itchaki, S. Ringelstein, N. Goldschmidt, C. Perry, S. Levi, A. Polliack, P. Ghia,
- 520 9_
- $a In recent years, considerable progress has been made in frontline therapy for elderly/physically unfit patients with CLL. The combination of obinutuzumab and chlorambucil (O-Clb) has been shown to prolong progression free survival (PFS, median PFS-31.5 months) and overall survival (OS) compared to chlorambucil alone. More recently, obinutuzumab given in combination with either ibrutinib or venetoclax improved PFS but not OS when compared to O-Clb. In this retrospective multinational, multicenter co-operative study, we evaluated the efficacy and safety of frontline treatment with O ± Clb in unfit patients with CLL, in a "real-world" setting. Patients with documented del (17p13.1)/TP53 mutation were excluded. A total of 437 patients (median age, 75.9 years; median CIRS score, 8; median creatinine clearance, 61.1 mL/min) were included. The clinical overall response rate was 80.3% (clinical complete and partial responses in 38.7% and 41.6% of patients, respectively). Median observation time was 14.1 months and estimated median PFS was 27.6 months (95% CI, 24.2-31.0). In a multivariate analysis, high-risk disease [del (11q22.3) and/or IGHV-unmutated], lymph nodes of diameter > 5 cm, obinutuzumab monotherapy and reduced cumulative dose of obinutuzumab, were all independently associated with shorter PFS. The median OS has not yet been reached and estimated 2-year OS is 88%. In conclusion, in a "real-world" setting, frontline treatment with O-Clb achieves PFS comparable to that reported in clinical trials. Inferior outcomes were noted in patients with del (11q22.3) and/or unmutated IGHV and those treated with obinutuzumab-monotherapy. Thus, O-Clb can be still considered as legitimate frontline therapy for unfit CLL patients with low-risk disease.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a humanizované monoklonální protilátky $x aplikace a dávkování $x škodlivé účinky $7 D061067
- 650 _2
- $a protokoly antitumorózní kombinované chemoterapie $x aplikace a dávkování $x škodlivé účinky $7 D000971
- 650 _2
- $a chlorambucil $x aplikace a dávkování $x škodlivé účinky $7 D002699
- 650 12
- $a chromozomální delece $7 D002872
- 650 _2
- $a lidské chromozomy, pár 17 $x genetika $7 D002886
- 650 _2
- $a přežití po terapii bez příznaků nemoci $7 D018572
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a chronická lymfatická leukemie $x farmakoterapie $x genetika $x mortalita $7 D015451
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a nádorový supresorový protein p53 $x genetika $7 D016159
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a pozorovací studie $7 D064888
- 700 1_
- $a Shaulov, Adir $u Hadassah Hebrew University Medical Center, Jerusalem, Israel.
- 700 1_
- $a Fineman, Riva $u Department of Hematology, Rambam Health Care Campus, Haifa, Israel.
- 700 1_
- $a Bašić-Kinda, Sandra $u University Hospital Centre Zagreb, Zagreb, Croatia.
- 700 1_
- $a Aviv, Ariel $u Department of Hematology, HaEmek Medical Center, Afula, Israel. Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel.
- 700 1_
- $a Wasik-Szczepanek, Ewa $u Department of Hematooncology, and Bone Marrow Transplantation Medical University, Lublin, Poland.
- 700 1_
- $a Jaksic, Ozren $u Dubrava University Hospital, Zagreb, Croatia.
- 700 1_
- $a Zdrenghea, Mihnea $u Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
- 700 1_
- $a Greenbaum, Uri $u Ben-Gurion University, Soroka University Medical Center, Beer Sheva, Israel.
- 700 1_
- $a Mandac, Inga $u Clinical Hospital Merkur, Zagreb, Croatia.
- 700 1_
- $a Simkovic, Martin $u University Hospital and Medical School Hradec Kralove, Hradec Kralove, Czech Republic.
- 700 1_
- $a Morawska, Marta $u St. John's Cancer Center, Lublin, Poland.
- 700 1_
- $a Benjamini, Ohad $u Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel. Hematology Division, Chaim Sheba Medical Center, Ramat Gan, Israel.
- 700 1_
- $a Spacek, Martin $u Charles University and General Hospital in Prague, Prague, Czech Republic.
- 700 1_
- $a Nemets, Anatoly $u Barzilai University Medical Center, Ashkelon, Israel.
- 700 1_
- $a Bairey, Osnat $u Rabin Medical Center, Beilinson Hospital; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- 700 1_
- $a Trentin, Livio $u Hematology Unit, University of Padua, Padua, Italy.
- 700 1_
- $a Ruchlemer, Rosa $u Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.
- 700 1_
- $a Laurenti, Luca $u Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
- 700 1_
- $a Stanca Ciocan, Oana $u Coltea Clinical Hospital, Bucharest, Romania.
- 700 1_
- $a Doubek, Michael $u Department of Internal Medicine-Hematology and Oncology, Medical Faculty of Masaryk University and University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Shvidel, Lev $u Department of Hematology, Kaplan Medical Center, Rehovot, Israel. Hebrew University of Jerusalem, Jerusalem, Israel.
- 700 1_
- $a Dali, Nagib $u Ziv Medical Center, Safed, Israel.
- 700 1_
- $a Mirás, Fátima $u Hospital 12 de Octubre, Madrid, Spain.
- 700 1_
- $a De Meûter, Anne $u Institut Jules Bordet, Brussels, Belgium.
- 700 1_
- $a Dimou, Maria $u Hematology Section - 1st Department Of Propaedeutic Internal Medicine, Laikon Hospital, Athens, Greece.
- 700 1_
- $a Mauro, Francesca R $u Hematology, Department of Translational and Precision Medicine, Sapienza University, Policlinico Umberto I, Rome, Italy.
- 700 1_
- $a Coscia, Marta $u Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
- 700 1_
- $a Bumbea, Horia $u Emergency University Clinical Hospital, Bucharest, Romania.
- 700 1_
- $a Szász, Róbert $u Division of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
- 700 1_
- $a Tadmor, Tamar $u Hematology, Bnai Zion Medical Center, Haifa, Israel.
- 700 1_
- $a Gutwein, Odit $u Assaf Ha'Rofeh, Tsrifin, Israel.
- 700 1_
- $a Gentile, Massimo $u Hematology Unit and Biotechnology Research Unit, A.O. of Cosenza, Cosenza, Italy.
- 700 1_
- $a Scarfò, Lydia $u Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy. Università Vita-Salute San Raffaele, Milan, Italy.
- 700 1_
- $a Tedeschi, Alessandra $u Department of Haematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
- 700 1_
- $a Sportoletti, Paolo $u Institute of Hematology and Center for Hemato-Oncological Research, Ospedale S. Maria della Misericordia, University of Perugia, Perugia, Italy.
- 700 1_
- $a Gimeno Vázquez, Eva $u Hospital del Mar, Barcelona, Spain.
- 700 1_
- $a Marquet, Juan $u Hematology and Hemotherapy, Hospital Universitario Ramón y Cajal, Madrid, Spain.
- 700 1_
- $a Assouline, Sarit $u Division of Hematology, Jewish General Hospital, Montreal, Quebec, Canada.
- 700 1_
- $a Papaioannou, Maria $u First Department of Internal Medicine, Division of Haematology, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- 700 1_
- $a Braester, Andrei $u Galilee Medical Center, Nahariya, Israel.
- 700 1_
- $a Levato, Luciano $u Department Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy.
- 700 1_
- $a Gregor, Michael $u Division of Hematology, Cantonal Hospital of Lucerne, Lucerne, Switzerland.
- 700 1_
- $a Rigolin, Gian M $u Hematology Section, Department of Medical Sciences, University of Ferrara-Azienda Ospedaliera-Universitaria di Ferrara, University of Ferrara, Ferrara, Italy.
- 700 1_
- $a Loscertales, Javier $u IIS-IP, Hospital Universitario de La Princesa, Madrid, Spain.
- 700 1_
- $a Medina Perez, Angeles $u Hospital Costa del Sol, Marbella, Spain.
- 700 1_
- $a Nijziel, Marten R $u Maxima Medical Center Eindhoven/Veldhoven, Eindhoven, Netherlands.
- 700 1_
- $a Popov, Viola M $u Hematology, Colentina Clinical Hospital, Bucharest, Romania.
- 700 1_
- $a Collado, Rosa $u Hospital General Universitario, Valencia, Spain.
- 700 1_
- $a Slavutsky, Irma $u Hospital Alvarez, Buenos Aires, Argentina.
- 700 1_
- $a Itchaki, Gilad $u Rabin Medical Center, Beilinson Hospital; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- 700 1_
- $a Ringelstein, Shimrit $u Department of Hematology, Rambam Health Care Campus, Haifa, Israel.
- 700 1_
- $a Goldschmidt, Neta $u Hadassah Hebrew University Medical Center, Jerusalem, Israel.
- 700 1_
- $a Perry, Chava $u Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.
- 700 1_
- $a Levi, Shai $u Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
- 700 1_
- $a Polliack, Aaron $u Hadassah Hebrew University Medical Center, Jerusalem, Israel.
- 700 1_
- $a Ghia, Paolo $u Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy. Università Vita-Salute San Raffaele, Milan, Italy.
- 773 0_
- $w MED00000251 $t American journal of hematology $x 1096-8652 $g Roč. 95, č. 6 (2020), s. 604-611
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32096887 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214125111 $b ABA008
- 999 __
- $a ok $b bmc $g 1595324 $s 1113681
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 95 $c 6 $d 604-611 $e 20200314 $i 1096-8652 $m American journal of hematology $n Am J Hematol $x MED00000251
- LZP __
- $a Pubmed-20201125
